Vext Science（VEXT）株式概要ベクストサイエンス社は、その子会社を通じて、米国の大麻産業において総合的な農業技術、サービス、不動産管理サービスを提供している。 詳細VEXT ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長4/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より96.5%で取引されている 収益は年間96.4%増加すると予測されています リスク分析意味のある時価総額がありません ( CA$70M )すべてのリスクチェックを見るVEXT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN59.3% undervaluedAnalystConsensusTarget•5mo agoAdult Use Expansion And Cultivation Gains Will Drive Stronger Long Term Cannabis Fundamentals501AN31.3% undervaluedAnalystLowTarget•4mo agoRegulatory Delays And Oversupply May Pressure Cannabis Margins Yet Long-Term Normalization Should Help800AN71.1% undervaluedAnalystHighTarget•5mo agoAdult Use Adoption And Yield Gains Will Drive Strong Future Cannabis Cash Flows600Top Analyst NarrativesAN59.3% undervaluedAnalystConsensusTarget•5mo agoAdult Use Expansion And Cultivation Gains Will Drive Stronger Long Term Cannabis Fundamentals501AN31.3% undervaluedAnalystLowTarget•4mo agoRegulatory Delays And Oversupply May Pressure Cannabis Margins Yet Long-Term Normalization Should Help800AN71.1% undervaluedAnalystHighTarget•5mo agoAdult Use Adoption And Yield Gains Will Drive Strong Future Cannabis Cash Flows600View all narrativesVext Science, Inc. 競合他社Decibel CannabisSymbol: TSXV:DBMarket cap: CA$69.2mPlanet 13 HoldingsSymbol: CNSX:PLTHMarket cap: CA$60.8mGrown Rogue InternationalSymbol: CNSX:GRINMarket cap: CA$135.0mC21 InvestmentsSymbol: CNSX:CXXIMarket cap: CA$41.3m価格と性能株価の高値、安値、推移の概要Vext Science過去の株価現在の株価CA$0.2852週高値CA$0.4052週安値CA$0.11ベータ0.771ヶ月の変化1.85%3ヶ月変化-1.79%1年変化150.00%3年間の変化0%5年間の変化-69.44%IPOからの変化-80.36%最新ニュースお知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026分析記事 • Jan 09Vext Science, Inc. (CSE:VEXT) Stock Rockets 35% But Many Are Still Ignoring The CompanyThose holding Vext Science, Inc. ( CSE:VEXT ) shares would be relieved that the share price has rebounded 35% in the...Buy Or Sell Opportunity • Dec 22Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CA$0.30. The fair value is estimated to be CA$0.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 94% in the next 2 years.New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$73.1m market cap, or US$53.0m).Reported Earnings • Nov 21Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.011 loss per share (further deteriorated from US$0.01 loss in 3Q 2024). Revenue: US$12.7m (up 41% from 3Q 2024). Net loss: US$2.63m (loss widened 5.3% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.最新情報をもっと見るRecent updatesお知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026分析記事 • Jan 09Vext Science, Inc. (CSE:VEXT) Stock Rockets 35% But Many Are Still Ignoring The CompanyThose holding Vext Science, Inc. ( CSE:VEXT ) shares would be relieved that the share price has rebounded 35% in the...Buy Or Sell Opportunity • Dec 22Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CA$0.30. The fair value is estimated to be CA$0.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 94% in the next 2 years.New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$73.1m market cap, or US$53.0m).Reported Earnings • Nov 21Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.011 loss per share (further deteriorated from US$0.01 loss in 3Q 2024). Revenue: US$12.7m (up 41% from 3Q 2024). Net loss: US$2.63m (loss widened 5.3% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.分析記事 • Nov 14Vext Science, Inc. (CSE:VEXT) Stock's 30% Dive Might Signal An Opportunity But It Requires Some ScrutinyVext Science, Inc. ( CSE:VEXT ) shareholders won't be pleased to see that the share price has had a very rough month...お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025分析記事 • Nov 07Vext Science, Inc.'s (CSE:VEXT) Intrinsic Value Is Potentially 80% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Vext Science fair value estimate is CA$0.45 Current share...Buy Or Sell Opportunity • Oct 15Now 21% undervaluedOver the last 90 days, the stock has risen 103% to CA$0.34. The fair value is estimated to be CA$0.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making.お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.分析記事 • Sep 26Vext Science, Inc. (CSE:VEXT) Soars 26% But It's A Story Of Risk Vs RewardDespite an already strong run, Vext Science, Inc. ( CSE:VEXT ) shares have been powering on, with a gain of 26% in the...Buy Or Sell Opportunity • Sep 25Now 22% undervaluedOver the last 90 days, the stock has risen 113% to CA$0.34. The fair value is estimated to be CA$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 21Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: US$0.006 loss per share (improved from US$0.018 loss in 2Q 2024). Revenue: US$13.4m (up 59% from 2Q 2024). Net loss: US$1.48m (loss narrowed 66% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 31%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.分析記事 • Aug 12Why Investors Shouldn't Be Surprised By Vext Science, Inc.'s (CSE:VEXT) 65% Share Price SurgeCNSX:VEXT 1 Year Share Price vs Fair Value Explore Vext Science's Fair Values from the Community and select yours...お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025分析記事 • Aug 10Health Check: How Prudently Does Vext Science (CSE:VEXT) Use Debt?CNSX:VEXT 1 Year Share Price vs Fair Value Explore Vext Science's Fair Values from the Community and select yours David...Price Target Changed • Jul 21Price target increased by 8.7% to CA$0.72Up from CA$0.67, the current price target is an average from 2 analysts. New target price is 326% above last closing price of CA$0.17. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.043 next year compared to a net loss per share of US$0.093 last year.Buy Or Sell Opportunity • Jul 07Now 27% undervaluedOver the last 90 days, the stock has risen 3.3% to CA$0.15. The fair value is estimated to be CA$0.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.分析記事 • Jun 28Even With A 28% Surge, Cautious Investors Are Not Rewarding Vext Science, Inc.'s (CSE:VEXT) Performance CompletelyVext Science, Inc. ( CSE:VEXT ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...New Risk • May 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (CA$35.6m market cap, or US$25.9m).分析記事 • May 28Vext Science, Inc.'s (CSE:VEXT) Intrinsic Value Is Potentially 70% Above Its Share PriceKey Insights The projected fair value for Vext Science is CA$0.21 based on 2 Stage Free Cash Flow to Equity Current...Reported Earnings • May 22First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.013 loss per share (improved from US$0.028 loss in 1Q 2024). Revenue: US$11.6m (up 38% from 1Q 2024). Net loss: US$3.33m (loss narrowed 47% from 1Q 2024). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.Reported Earnings • Mar 31Full year 2024 earnings released: US$0.093 loss per share (vs US$0.027 profit in FY 2023)Full year 2024 results: US$0.093 loss per share (down from US$0.027 profit in FY 2023). Revenue: US$36.0m (up 3.4% from FY 2023). Net loss: US$22.4m (down US$26.8m from profit in FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.分析記事 • Mar 27The Market Lifts Vext Science, Inc. (CSE:VEXT) Shares 28% But It Can Do MoreVext Science, Inc. ( CSE:VEXT ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025分析記事 • Feb 07Take Care Before Diving Into The Deep End On Vext Science, Inc. (CSE:VEXT)With a median price-to-sales (or "P/S") ratio of close to 0.8x in the Pharmaceuticals industry in Canada, you could be...New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$47.0m market cap, or US$33.6m).Reported Earnings • Nov 23Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.01 loss per share. Revenue: US$8.99m (up 11% from 3Q 2023). Net loss: US$2.50m (loss widened 36% from 3Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$48.2m market cap, or US$34.2m).お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024分析記事 • Oct 24It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It LooksThe Vext Science, Inc. ( CSE:VEXT ) share price has fared very poorly over the last month, falling by a substantial...お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.Price Target Changed • Oct 06Price target decreased by 14% to CA$0.57Down from CA$0.67, the current price target is an average from 2 analysts. New target price is 161% above last closing price of CA$0.22. Stock is down 23% over the past year. The company is forecast to post a net loss per share of US$0.09 compared to earnings per share of US$0.027 last year.Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024Price Target Changed • Jul 01Price target increased by 12% to CA$0.75Up from CA$0.67, the current price target is an average from 4 analysts. New target price is 226% above last closing price of CA$0.23. Stock is down 12% over the past year. The company posted earnings per share of US$0.027 last year.分析記事 • Jun 18Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% CheaperVext Science, Inc. ( CSE:VEXT ) shares have had a horrible month, losing 30% after a relatively good period beforehand...Recent Insider Transactions • Jun 09Chief Financial Officer recently bought CA$63k worth of stockOn the 3rd of June, Trevor Smith bought around 247k shares on-market at roughly CA$0.26 per share. This transaction increased Trevor's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Trevor's only on-market trade for the last 12 months.お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024New Risk • May 12New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 129% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (CA$74.9m market cap, or US$54.8m).お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$68.7m market cap, or US$50.7m).お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.分析記事 • Jan 16There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is UndemandingWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 13x, you may consider Vext...Reported Earnings • Nov 29Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 32%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$56.5m market cap, or US$41.4m).お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.分析記事 • Sep 29Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Reported Earnings • Aug 24Second quarter 2023 earnings: EPS exceeds analyst expectationsSecond quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023分析記事 • Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.Reported Earnings • May 27First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023Price Target Changed • May 10Price target increased by 7.2% to CA$1.30Up from CA$1.21, the current price target is an average from 3 analysts. New target price is 341% above last closing price of CA$0.29. Stock is down 30% over the past year. The company posted earnings per share of US$0.079 last year.Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.分析記事 • Jan 17Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Board Change • Dec 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 17Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million.Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million on December 15, 2022. Consideration an aggregate of $750,000 in cash paid upon execution of the Purchase Agreements, an aggregate of $3.0 million principal amount of unsecured promissory notes, an aggregate of approximately $6 million principal amount of unsecured promissory notes to be issued by Vapen Ohio on the earlier of (i) closing of the Proposed APP Acquisitions and (ii) January 1, 2023, an aggregate of 8,999,989 Common Shares, at a deemed price of $0.156 per share, issued upon execution of the Purchase Agreements subject to certain customary adjustments. The Proposed APP Acquisition is subject to regulatory approvals and other customary conditions precedent. Proposed Transaction are expected to close by the end of the second quarter of 2023. Eight Capital acted as financial advisor to Vext and its board of directors. McMillan LLP acted as legal counsel to Vext and Bianchi & Brandt acted as legal counsel to Vext. Gordon Bibart, LLC acted as legal counsel to APP. Eight Capital acted as Fairness Opinion Provider to Vext.お知らせ • Dec 16Vext Science, Inc. Announces Board ChangesVext Science, Inc. announced that the Board has accepted the resignation of Mr. David Eaton from the Board effective December 15, 2022 and after the Company's Annual General Meeting. In conjunction with Mr. Eaton's departure, Mr. David Johns has been appointed to the Board, effective December 15, 2022. Mr. Johns has demonstrated experience in the services and IT industry and sits on the boards of several companies. He is currently the Managing Director of APP in Ohio, which produces THC and CBD infused medical marijuana products for patients across the state. Prior to joining APP, David was the SVP and CIO at Ascena Retail Group Inc, where he successfully implemented large-scale IT transformation and project efforts. Previously, David led the Global Information Technology, Global Business Shared Services and Corporate Services Sourcing functions at Owens Corning. He joined Owens Corning in 1994, and in this latest role as SVP and CIO, David had oversight for all Owens Corning business shared service centers, manufacturing technology, project portfolio management, sourcing and information systems. Prior to his experience at Owens Corning, David held technology positions with Honeywell, Inc. and Time Warner. In both of these roles, he orchestrated major computer systems development and management activities at both the division and corporate levels. David holds a Bachelor of Science in Computer Science Engineering from The Ohio State University and a Master of Business Administration from the University of Dayton. David was a scholarship athlete while at The Ohio State University. He was inducted into the CIO Hall of Fame in 2009 and was named one of Computerworld's Premier 100 information technology leaders for 2012.分析記事 • Dec 09Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For NowShareholders of Vext Science, Inc. ( CSE:VEXT ) will have been dismayed by the negative share price return over the...Price Target Changed • Nov 23Price target decreased to CA$1.24Down from CA$1.46, the current price target is an average from 4 analysts. New target price is 450% above last closing price of CA$0.23. Stock is down 70% over the past year. The company posted earnings per share of US$0.036 last year.Reported Earnings • Nov 19Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022Vext Science, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 17, 2022Price Target Changed • Oct 25Price target decreased to CA$1.46Down from CA$1.58, the current price target is an average from 4 analysts. New target price is 396% above last closing price of CA$0.29. Stock is down 63% over the past year. The company posted earnings per share of US$0.036 last year.お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 15, 2022Vext Science, Inc., Annual General Meeting, Dec 15, 2022.分析記事 • Sep 29We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Sep 21Vext Science Announces Filing of Provisional Patent ApplicationVext Science, Inc. announced that its research and development team has filed a provisional patent application (the "Patent") with the United States Patent Office ("USPTO") in collaboration with researchers at BioSciTech and Arizona State University ("ASU"). The patent covers new crystalline forms of phytocannabinoid acids, a class of non-psychoactive natural products isolated from the cannabis sativa plant, several of which have been proven to be pharmaceutically active. Crystallized phytocannabinoids have been proven to be the most effective method to ensure pharmaceutical level purity for processing and production. These crystalline forms also have improved shelf-life and bioavailability compared to the natural forms. Studies have also indicated that phytocannabinoid acids have anti-inflammatory properties, and may be applicable as anti-virals.お知らせ • Sep 16Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million.Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. entered into a share purchase agreement to acquire a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million on September 3, 2022. Sopica purchased 112,486 Class A Multiple Voting Shares at a price of $26.67 per share, representing 16.72% of the issued and outstanding Multiple Voting Shares and 13.65% of the issued and outstanding common shares of VEXT (assuming conversion of the acquired Multiple Voting Shares). Immediately prior to the Transaction, Nguyen beneficially owned or otherwise exercised control or direction over 605,747 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 options to purchase Subordinate Voting Shares (“Options”), representing approximately 90.04% of the issued and outstanding Multiple Voting Shares and approximately 47.07% of the issued and outstanding Subordinate Voting Shares (on an a partially diluted basis). As a result of the Transaction, Nguyen beneficially owns or otherwise exercises control or direction over 493,261 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 Options, representing approximately 73.32% of the issued and outstanding Multiple Voting Shares and approximately 42.12% of the issued and outstanding Subordinate Voting Shares (on a partially diluted basis). Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. completed the acquisition of a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen on September 14, 2022.Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 31%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Aug 24Director recently bought CA$53k worth of stockOn the 16th of August, Mark Opzoomer bought around 125k shares on-market at roughly CA$0.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$95k more in shares than they have sold in the last 12 months.お知らせ • Aug 23Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022Vext Science, Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022お知らせ • Jun 16Vext Science, Inc. Announces CFO TransitionVext Science, Inc. announced that current Chief Financial Officer Daniel Engel, has decided to leave the Company to pursue an opportunity with a private equity backed company. Stephan Bankosz will take over as Vext's interim CFO and Corporate Secretary while the Company considers internal and external candidates. Mr. Bankosz was appointed CFO of New Gen Holdings, Inc., ("New Gen"), Vext's primary operating subsidiary, in January 2021. Additional finance resources will be recruited under Stephan to support Vext's growth plans. Mr. Bankosz has over 25 years experience in financial management, operational control and riskmanagement at leading manufacturing and distribution companies throughout the United States. His proven expertise in managing corporate profitability for growth companies has been valuable since his appointment as CFO of New Gen in January 2021, and will continue to be beneficial as Vext continues to execute its growth plans in Arizona and Ohio. Mr. Bankosz holds a Bachelor's degree in accounting and management information systems and is a Microsoft Certified Systems Engineer, with specialized certification in over 20 accounting and distribution programs.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 92% growth forecast for the industry in Canada.お知らせ • May 27Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022Vext Science, Inc. announced that they will report Q1, 2022 results After-Market on May 30, 2022分析記事 • Apr 29Vext Science (CSE:VEXT) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Price Target Changed • Apr 27Price target decreased to CA$1.84Down from CA$1.99, the current price target is an average from 4 analysts. New target price is 338% above last closing price of CA$0.42. Stock is down 58% over the past year. The company posted earnings per share of US$0.036 last year.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 108% growth forecast for the pharmaceuticals industry in Canada.お知らせ • Apr 21Vext Science, Inc. Announces Executive ChangesVext Science, Inc. announced that senior financial and operations executive Daniel Engel will join the Company on May 2, 2022, as the Company's CFO. Current CFO Vahan Ajamian will be staying for a planned transition period through May 31, 2022.お知らせ • Apr 15Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022Vext Science, Inc. announced that they will report Q4, 2021 results Pre-Market on Apr 20, 2022Price Target Changed • Apr 04Price target decreased to CA$1.99Down from CA$2.25, the current price target is an average from 3 analysts. New target price is 231% above last closing price of CA$0.60. Stock is down 36% over the past year. The company posted earnings per share of US$0.023 last year.Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.お知らせ • Feb 11Vext Science, Inc. Appoints Mark W. Opzoomer as Board of DirectorVext Science, Inc. announced that Mark W. Opzoomer, a highly experienced global executive and director, has been appointed to the Company's board of directors effective immediately. Mr. Opzoomer is currently Managing Director at Bond Capital Partners, a mid-market private equity investor and advisory firm, which he founded in 2004. Mr. Opzoomer is also currently Chairman of Trint Limited (SaaS AI media creation workflow platform) and a director of the Mark'ennovy group (R&D driven custom contact lens maker and marketer). Mark recently stepped down as Chairman of Somo Global Ltd. in January on the successful sale to CI&T Inc, both leaders in digital transformation services. Mark served 12 years on the board of Entertainment One Ltd. before its $3.8 billion acquisition by Hasbro Inc. in December 2019, latterly as Senior Independent Director, and included three-year periods as Chair of each of the Audit Committee and Remuneration Committee.Reported Earnings • Nov 20Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.分析記事 • Nov 15Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.分析記事 • Jul 15Is Vext Science (CSE:VEXT) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...株主還元VEXTCA PharmaceuticalsCA 市場7D-6.8%-6.3%-0.2%1Y150.0%44.6%32.6%株主還元を見る業界別リターン: VEXT過去 1 年間で44.6 % の収益を上げたCanadian Pharmaceuticals業界を上回りました。リターン対市場: VEXT過去 1 年間で32.6 % の収益を上げたCanadian市場を上回りました。価格変動Is VEXT's price volatile compared to industry and market?VEXT volatilityVEXT Average Weekly Movement10.7%Pharmaceuticals Industry Average Movement11.2%Market Average Movement10.3%10% most volatile stocks in CA Market18.1%10% least volatile stocks in CA Market3.9%安定した株価: VEXT 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: VEXTの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aEric Offenbergerwww.vextscience.comベクストサイエンス社は、その子会社を通じて、米国の大麻産業において総合的な農業技術、サービス、不動産管理サービスを提供している。同社は栽培施設、製造ユニット、調剤薬局を所有・管理し、THCとCBDのカートリッジ、濃縮液、エディブルの栽培、抽出、製造、販売に携わっている。同社はまた、小売調剤薬局活動や、Vapen、Pure Touch、Appalachian Pharm、Herbal Wellness、Revibeブランドの大麻THCおよびヘンプCBD製品の卸売販売も行っている。さらに、運営契約や直接販売を通じて、大麻分野の事業体に経営、助言、栽培、非大麻製品、薬局サービスを提供している。同社は以前、Vapen MJ Ventures Corporationとして知られていたが、2019年11月にVext Science, Inc.に社名を変更した。Vext Science, Inc.は2015年に法人化され、アリゾナ州フェニックスに本社を置いている。もっと見るVext Science, Inc. 基礎のまとめVext Science の収益と売上を時価総額と比較するとどうか。VEXT 基礎統計学時価総額CA$70.29m収益（TTM）-CA$24.73m売上高(TTM)CA$70.59m1.0xP/Sレシオ-2.8xPER（株価収益率VEXT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計VEXT 損益計算書（TTM）収益US$51.37m売上原価US$36.91m売上総利益US$14.46mその他の費用US$32.45m収益-US$17.99m直近の収益報告Dec 31, 2025次回決算日May 21, 2026一株当たり利益（EPS）-0.072グロス・マージン28.14%純利益率-35.03%有利子負債／自己資本比率56.0%VEXT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 11:49終値2026/05/20 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Vext Science, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Matt BottomleyCanaccord GenuityShaan MirCanaccord GenuityNeal GilmerHaywood Securities Inc.4 その他のアナリストを表示
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
分析記事 • Jan 09Vext Science, Inc. (CSE:VEXT) Stock Rockets 35% But Many Are Still Ignoring The CompanyThose holding Vext Science, Inc. ( CSE:VEXT ) shares would be relieved that the share price has rebounded 35% in the...
Buy Or Sell Opportunity • Dec 22Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CA$0.30. The fair value is estimated to be CA$0.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 94% in the next 2 years.
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$73.1m market cap, or US$53.0m).
Reported Earnings • Nov 21Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.011 loss per share (further deteriorated from US$0.01 loss in 3Q 2024). Revenue: US$12.7m (up 41% from 3Q 2024). Net loss: US$2.63m (loss widened 5.3% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
お知らせ • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
お知らせ • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
分析記事 • Jan 09Vext Science, Inc. (CSE:VEXT) Stock Rockets 35% But Many Are Still Ignoring The CompanyThose holding Vext Science, Inc. ( CSE:VEXT ) shares would be relieved that the share price has rebounded 35% in the...
Buy Or Sell Opportunity • Dec 22Now 25% undervalued after recent price dropOver the last 90 days, the stock has fallen 10% to CA$0.30. The fair value is estimated to be CA$0.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 94% in the next 2 years.
New Risk • Dec 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 15% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (41% net debt to equity). Share price has been volatile over the past 3 months (15% average weekly change). Market cap is less than US$100m (CA$73.1m market cap, or US$53.0m).
Reported Earnings • Nov 21Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.011 loss per share (further deteriorated from US$0.01 loss in 3Q 2024). Revenue: US$12.7m (up 41% from 3Q 2024). Net loss: US$2.63m (loss widened 5.3% from 3Q 2024). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 41%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 110 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 14Vext Science, Inc. (CSE:VEXT) Stock's 30% Dive Might Signal An Opportunity But It Requires Some ScrutinyVext Science, Inc. ( CSE:VEXT ) shareholders won't be pleased to see that the share price has had a very rough month...
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
分析記事 • Nov 07Vext Science, Inc.'s (CSE:VEXT) Intrinsic Value Is Potentially 80% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Vext Science fair value estimate is CA$0.45 Current share...
Buy Or Sell Opportunity • Oct 15Now 21% undervaluedOver the last 90 days, the stock has risen 103% to CA$0.34. The fair value is estimated to be CA$0.44, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.
分析記事 • Sep 26Vext Science, Inc. (CSE:VEXT) Soars 26% But It's A Story Of Risk Vs RewardDespite an already strong run, Vext Science, Inc. ( CSE:VEXT ) shares have been powering on, with a gain of 26% in the...
Buy Or Sell Opportunity • Sep 25Now 22% undervaluedOver the last 90 days, the stock has risen 113% to CA$0.34. The fair value is estimated to be CA$0.43, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.1% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 21Second quarter 2025 earnings: EPS exceeds analyst expectationsSecond quarter 2025 results: US$0.006 loss per share (improved from US$0.018 loss in 2Q 2024). Revenue: US$13.4m (up 59% from 2Q 2024). Net loss: US$1.48m (loss narrowed 66% from 2Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 31%. Revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 12Why Investors Shouldn't Be Surprised By Vext Science, Inc.'s (CSE:VEXT) 65% Share Price SurgeCNSX:VEXT 1 Year Share Price vs Fair Value Explore Vext Science's Fair Values from the Community and select yours...
お知らせ • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
分析記事 • Aug 10Health Check: How Prudently Does Vext Science (CSE:VEXT) Use Debt?CNSX:VEXT 1 Year Share Price vs Fair Value Explore Vext Science's Fair Values from the Community and select yours David...
Price Target Changed • Jul 21Price target increased by 8.7% to CA$0.72Up from CA$0.67, the current price target is an average from 2 analysts. New target price is 326% above last closing price of CA$0.17. Stock is down 32% over the past year. The company is forecast to post a net loss per share of US$0.043 next year compared to a net loss per share of US$0.093 last year.
Buy Or Sell Opportunity • Jul 07Now 27% undervaluedOver the last 90 days, the stock has risen 3.3% to CA$0.15. The fair value is estimated to be CA$0.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
分析記事 • Jun 28Even With A 28% Surge, Cautious Investors Are Not Rewarding Vext Science, Inc.'s (CSE:VEXT) Performance CompletelyVext Science, Inc. ( CSE:VEXT ) shareholders are no doubt pleased to see that the share price has bounced 28% in the...
New Risk • May 30New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 26% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Earnings have declined by 44% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (CA$35.6m market cap, or US$25.9m).
分析記事 • May 28Vext Science, Inc.'s (CSE:VEXT) Intrinsic Value Is Potentially 70% Above Its Share PriceKey Insights The projected fair value for Vext Science is CA$0.21 based on 2 Stage Free Cash Flow to Equity Current...
Reported Earnings • May 22First quarter 2025 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2025 results: US$0.013 loss per share (improved from US$0.028 loss in 1Q 2024). Revenue: US$11.6m (up 38% from 1Q 2024). Net loss: US$3.33m (loss narrowed 47% from 1Q 2024). Revenue exceeded analyst estimates by 17%. Earnings per share (EPS) also surpassed analyst estimates by 31%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
お知らせ • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
お知らせ • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.
Reported Earnings • Mar 31Full year 2024 earnings released: US$0.093 loss per share (vs US$0.027 profit in FY 2023)Full year 2024 results: US$0.093 loss per share (down from US$0.027 profit in FY 2023). Revenue: US$36.0m (up 3.4% from FY 2023). Net loss: US$22.4m (down US$26.8m from profit in FY 2023). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
分析記事 • Mar 27The Market Lifts Vext Science, Inc. (CSE:VEXT) Shares 28% But It Can Do MoreVext Science, Inc. ( CSE:VEXT ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...
お知らせ • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025
分析記事 • Feb 07Take Care Before Diving Into The Deep End On Vext Science, Inc. (CSE:VEXT)With a median price-to-sales (or "P/S") ratio of close to 0.8x in the Pharmaceuticals industry in Canada, you could be...
New Risk • Nov 23New major risk - Revenue and earnings growthEarnings have declined by 10% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$47.0m market cap, or US$33.6m).
Reported Earnings • Nov 23Third quarter 2024 earnings: EPS and revenues miss analyst expectationsThird quarter 2024 results: US$0.01 loss per share. Revenue: US$8.99m (up 11% from 3Q 2023). Net loss: US$2.50m (loss widened 36% from 3Q 2023). Revenue missed analyst estimates by 2.7%. Earnings per share (EPS) also missed analyst estimates by 40%. Revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada.
New Risk • Nov 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (CA$48.2m market cap, or US$34.2m).
お知らせ • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024
分析記事 • Oct 24It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It LooksThe Vext Science, Inc. ( CSE:VEXT ) share price has fared very poorly over the last month, falling by a substantial...
お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.
Price Target Changed • Oct 06Price target decreased by 14% to CA$0.57Down from CA$0.67, the current price target is an average from 2 analysts. New target price is 161% above last closing price of CA$0.22. Stock is down 23% over the past year. The company is forecast to post a net loss per share of US$0.09 compared to earnings per share of US$0.027 last year.
Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024
Price Target Changed • Jul 01Price target increased by 12% to CA$0.75Up from CA$0.67, the current price target is an average from 4 analysts. New target price is 226% above last closing price of CA$0.23. Stock is down 12% over the past year. The company posted earnings per share of US$0.027 last year.
分析記事 • Jun 18Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% CheaperVext Science, Inc. ( CSE:VEXT ) shares have had a horrible month, losing 30% after a relatively good period beforehand...
Recent Insider Transactions • Jun 09Chief Financial Officer recently bought CA$63k worth of stockOn the 3rd of June, Trevor Smith bought around 247k shares on-market at roughly CA$0.26 per share. This transaction increased Trevor's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Trevor's only on-market trade for the last 12 months.
お知らせ • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024
New Risk • May 12New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 129% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (15% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Market cap is less than US$100m (CA$74.9m market cap, or US$54.8m).
お知らせ • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$68.7m market cap, or US$50.7m).
お知らせ • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.
分析記事 • Jan 16There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is UndemandingWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 13x, you may consider Vext...
Reported Earnings • Nov 29Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 32%. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
お知らせ • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023
お知らせ • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.
New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$56.5m market cap, or US$41.4m).
お知らせ • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.
分析記事 • Sep 29Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Reported Earnings • Aug 24Second quarter 2023 earnings: EPS exceeds analyst expectationsSecond quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings.
お知らせ • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023
分析記事 • Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.
Reported Earnings • May 27First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 17% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023
Price Target Changed • May 10Price target increased by 7.2% to CA$1.30Up from CA$1.21, the current price target is an average from 3 analysts. New target price is 341% above last closing price of CA$0.29. Stock is down 30% over the past year. The company posted earnings per share of US$0.079 last year.
Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
分析記事 • Jan 17Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Board Change • Dec 21Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 17Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million.Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million on December 15, 2022. Consideration an aggregate of $750,000 in cash paid upon execution of the Purchase Agreements, an aggregate of $3.0 million principal amount of unsecured promissory notes, an aggregate of approximately $6 million principal amount of unsecured promissory notes to be issued by Vapen Ohio on the earlier of (i) closing of the Proposed APP Acquisitions and (ii) January 1, 2023, an aggregate of 8,999,989 Common Shares, at a deemed price of $0.156 per share, issued upon execution of the Purchase Agreements subject to certain customary adjustments. The Proposed APP Acquisition is subject to regulatory approvals and other customary conditions precedent. Proposed Transaction are expected to close by the end of the second quarter of 2023. Eight Capital acted as financial advisor to Vext and its board of directors. McMillan LLP acted as legal counsel to Vext and Bianchi & Brandt acted as legal counsel to Vext. Gordon Bibart, LLC acted as legal counsel to APP. Eight Capital acted as Fairness Opinion Provider to Vext.
お知らせ • Dec 16Vext Science, Inc. Announces Board ChangesVext Science, Inc. announced that the Board has accepted the resignation of Mr. David Eaton from the Board effective December 15, 2022 and after the Company's Annual General Meeting. In conjunction with Mr. Eaton's departure, Mr. David Johns has been appointed to the Board, effective December 15, 2022. Mr. Johns has demonstrated experience in the services and IT industry and sits on the boards of several companies. He is currently the Managing Director of APP in Ohio, which produces THC and CBD infused medical marijuana products for patients across the state. Prior to joining APP, David was the SVP and CIO at Ascena Retail Group Inc, where he successfully implemented large-scale IT transformation and project efforts. Previously, David led the Global Information Technology, Global Business Shared Services and Corporate Services Sourcing functions at Owens Corning. He joined Owens Corning in 1994, and in this latest role as SVP and CIO, David had oversight for all Owens Corning business shared service centers, manufacturing technology, project portfolio management, sourcing and information systems. Prior to his experience at Owens Corning, David held technology positions with Honeywell, Inc. and Time Warner. In both of these roles, he orchestrated major computer systems development and management activities at both the division and corporate levels. David holds a Bachelor of Science in Computer Science Engineering from The Ohio State University and a Master of Business Administration from the University of Dayton. David was a scholarship athlete while at The Ohio State University. He was inducted into the CIO Hall of Fame in 2009 and was named one of Computerworld's Premier 100 information technology leaders for 2012.
分析記事 • Dec 09Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For NowShareholders of Vext Science, Inc. ( CSE:VEXT ) will have been dismayed by the negative share price return over the...
Price Target Changed • Nov 23Price target decreased to CA$1.24Down from CA$1.46, the current price target is an average from 4 analysts. New target price is 450% above last closing price of CA$0.23. Stock is down 70% over the past year. The company posted earnings per share of US$0.036 last year.
Reported Earnings • Nov 19Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 11Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022Vext Science, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 17, 2022
Price Target Changed • Oct 25Price target decreased to CA$1.46Down from CA$1.58, the current price target is an average from 4 analysts. New target price is 396% above last closing price of CA$0.29. Stock is down 63% over the past year. The company posted earnings per share of US$0.036 last year.
お知らせ • Oct 15Vext Science, Inc., Annual General Meeting, Dec 15, 2022Vext Science, Inc., Annual General Meeting, Dec 15, 2022.
分析記事 • Sep 29We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Sep 21Vext Science Announces Filing of Provisional Patent ApplicationVext Science, Inc. announced that its research and development team has filed a provisional patent application (the "Patent") with the United States Patent Office ("USPTO") in collaboration with researchers at BioSciTech and Arizona State University ("ASU"). The patent covers new crystalline forms of phytocannabinoid acids, a class of non-psychoactive natural products isolated from the cannabis sativa plant, several of which have been proven to be pharmaceutically active. Crystallized phytocannabinoids have been proven to be the most effective method to ensure pharmaceutical level purity for processing and production. These crystalline forms also have improved shelf-life and bioavailability compared to the natural forms. Studies have also indicated that phytocannabinoid acids have anti-inflammatory properties, and may be applicable as anti-virals.
お知らせ • Sep 16Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million.Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. entered into a share purchase agreement to acquire a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million on September 3, 2022. Sopica purchased 112,486 Class A Multiple Voting Shares at a price of $26.67 per share, representing 16.72% of the issued and outstanding Multiple Voting Shares and 13.65% of the issued and outstanding common shares of VEXT (assuming conversion of the acquired Multiple Voting Shares). Immediately prior to the Transaction, Nguyen beneficially owned or otherwise exercised control or direction over 605,747 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 options to purchase Subordinate Voting Shares (“Options”), representing approximately 90.04% of the issued and outstanding Multiple Voting Shares and approximately 47.07% of the issued and outstanding Subordinate Voting Shares (on an a partially diluted basis). As a result of the Transaction, Nguyen beneficially owns or otherwise exercises control or direction over 493,261 Multiple Voting Shares, 1,425,300 Subordinate Voting Shares and 100,000 Options, representing approximately 73.32% of the issued and outstanding Multiple Voting Shares and approximately 42.12% of the issued and outstanding Subordinate Voting Shares (on a partially diluted basis). Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. completed the acquisition of a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen on September 14, 2022.
Reported Earnings • Aug 25Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 31%, compared to a 24% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Aug 24Director recently bought CA$53k worth of stockOn the 16th of August, Mark Opzoomer bought around 125k shares on-market at roughly CA$0.42 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought CA$95k more in shares than they have sold in the last 12 months.
お知らせ • Aug 23Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022Vext Science, Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022
お知らせ • Jun 16Vext Science, Inc. Announces CFO TransitionVext Science, Inc. announced that current Chief Financial Officer Daniel Engel, has decided to leave the Company to pursue an opportunity with a private equity backed company. Stephan Bankosz will take over as Vext's interim CFO and Corporate Secretary while the Company considers internal and external candidates. Mr. Bankosz was appointed CFO of New Gen Holdings, Inc., ("New Gen"), Vext's primary operating subsidiary, in January 2021. Additional finance resources will be recruited under Stephan to support Vext's growth plans. Mr. Bankosz has over 25 years experience in financial management, operational control and riskmanagement at leading manufacturing and distribution companies throughout the United States. His proven expertise in managing corporate profitability for growth companies has been valuable since his appointment as CFO of New Gen in January 2021, and will continue to be beneficial as Vext continues to execute its growth plans in Arizona and Ohio. Mr. Bankosz holds a Bachelor's degree in accounting and management information systems and is a Microsoft Certified Systems Engineer, with specialized certification in over 20 accounting and distribution programs.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 92% growth forecast for the industry in Canada.
お知らせ • May 27Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022Vext Science, Inc. announced that they will report Q1, 2022 results After-Market on May 30, 2022
分析記事 • Apr 29Vext Science (CSE:VEXT) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Price Target Changed • Apr 27Price target decreased to CA$1.84Down from CA$1.99, the current price target is an average from 4 analysts. New target price is 338% above last closing price of CA$0.42. Stock is down 58% over the past year. The company posted earnings per share of US$0.036 last year.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 108% growth forecast for the pharmaceuticals industry in Canada.
お知らせ • Apr 21Vext Science, Inc. Announces Executive ChangesVext Science, Inc. announced that senior financial and operations executive Daniel Engel will join the Company on May 2, 2022, as the Company's CFO. Current CFO Vahan Ajamian will be staying for a planned transition period through May 31, 2022.
お知らせ • Apr 15Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022Vext Science, Inc. announced that they will report Q4, 2021 results Pre-Market on Apr 20, 2022
Price Target Changed • Apr 04Price target decreased to CA$1.99Down from CA$2.25, the current price target is an average from 3 analysts. New target price is 231% above last closing price of CA$0.60. Stock is down 36% over the past year. The company posted earnings per share of US$0.023 last year.
Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
お知らせ • Feb 11Vext Science, Inc. Appoints Mark W. Opzoomer as Board of DirectorVext Science, Inc. announced that Mark W. Opzoomer, a highly experienced global executive and director, has been appointed to the Company's board of directors effective immediately. Mr. Opzoomer is currently Managing Director at Bond Capital Partners, a mid-market private equity investor and advisory firm, which he founded in 2004. Mr. Opzoomer is also currently Chairman of Trint Limited (SaaS AI media creation workflow platform) and a director of the Mark'ennovy group (R&D driven custom contact lens maker and marketer). Mark recently stepped down as Chairman of Somo Global Ltd. in January on the successful sale to CI&T Inc, both leaders in digital transformation services. Mark served 12 years on the board of Entertainment One Ltd. before its $3.8 billion acquisition by Hasbro Inc. in December 2019, latterly as Senior Independent Director, and included three-year periods as Chair of each of the Audit Committee and Remuneration Committee.
Reported Earnings • Nov 20Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
分析記事 • Nov 15Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.
分析記事 • Jul 15Is Vext Science (CSE:VEXT) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
